X hits on this document

524 views

0 shares

0 downloads

0 comments

108 / 170

6

about the number of patients who had baseline Diabetic Kidney Disease. If I could

7

please project slide 3-52, so this slide summarizes the prevalence of micro-vascular

8

complications of type 2 diabetes in our population. I think we may need to comeback to

9

you after the break on the breakdown by severity of renal impairment. The vast majority

10

of the patients who had an abnormal creatinine clearance were between 50 and 80. So

11

they fall into the mild category. I do want to remind the committee that we have an on

12

going clinical trial, randomized clinical trial examining patients who have both moderate

13

and severe renal impairment.

19

DR. WOLF: We did not see evidence for pancreatic injury in our non

20

clinical safety studies, and I will now ask Dr. Roland Chen to come to the podium to

21

describe our clinical experience in pancreatitis and the clinical development program.

15

Two quick questions, number one, do you have any further information on tumors of the

16

skin either in animals or humans, you talked about ulcerations a little bit, and any more

17

information on pancreatitis whether it’s acute or chronic or silent with elevation of

18

pancreatic enzymes either in animal or human?

23

program were frequent and balanced between the treatment groups. Can I have slide 27-

24

1 please. This slide summarizes the adverse events of pancreatitis in our phase 2b3 pool

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

1

whether they were based on a hypercholesterolemia or not. Approximately half of the

107

14

DR. BURMAN: Thank you. I had a question for the Sponsor as well.

22

DR. CHEN: Events of pancreatitis seeing in the Saxagliptin clinical

2

3

patients we had based on hypercholesterolemia were on a Statin.

DR. TEERLINK: That’s very helpful. My question was in regards to the

4

5

stages of chronic kidney disease that patients had in enrollment before at baseline.

DR. WOLF: Let me first share some data with you, we were asked also

Document info
Document views524
Page views524
Page last viewedFri Dec 09 22:03:32 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments